These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 39013795)

  • 1. Therapeutic potential and recent progression of BTK inhibitors against rheumatoid arthritis.
    Paliwal S; Bawa S; Shalmali N; Tonk RK
    Chem Biol Drug Des; 2024 Jul; 104(1):e14582. PubMed ID: 39013795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Bruton's Tyrosine Kinase Inhibitors for Rheumatoid Arthritis.
    Lv J; Wu J; He F; Qu Y; Zhang Q; Yu C
    Curr Med Chem; 2018; 25(42):5847-5859. PubMed ID: 29546831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel tricyclic BTK inhibitor suppresses B cell responses and osteoclastic bone erosion in rheumatoid arthritis.
    Liu YT; Ding HH; Lin ZM; Wang Q; Chen L; Liu SS; Yang XQ; Zhu FH; Huang YT; Cao SQ; Yang FM; Song ZL; Ding J; Geng MY; Xie H; Zhang A; He SJ; Zuo JP
    Acta Pharmacol Sin; 2021 Oct; 42(10):1653-1664. PubMed ID: 33441995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures.
    Ringheim GE; Wampole M; Oberoi K
    Front Immunol; 2021; 12():662223. PubMed ID: 34803999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis.
    Di Paolo JA; Huang T; Balazs M; Barbosa J; Barck KH; Bravo BJ; Carano RA; Darrow J; Davies DR; DeForge LE; Diehl L; Ferrando R; Gallion SL; Giannetti AM; Gribling P; Hurez V; Hymowitz SG; Jones R; Kropf JE; Lee WP; Maciejewski PM; Mitchell SA; Rong H; Staker BL; Whitney JA; Yeh S; Young WB; Yu C; Zhang J; Reif K; Currie KS
    Nat Chem Biol; 2011 Jan; 7(1):41-50. PubMed ID: 21113169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Bruton's tyrosine kinase in B cells and malignancies.
    Pal Singh S; Dammeijer F; Hendriks RW
    Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of Bruton's tyrosine kinase in the immune system and disease.
    McDonald C; Xanthopoulos C; Kostareli E
    Immunology; 2021 Dec; 164(4):722-736. PubMed ID: 34534359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.
    Whang JA; Chang BY
    Drug Discov Today; 2014 Aug; 19(8):1200-4. PubMed ID: 24721226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.
    Honigberg LA; Smith AM; Sirisawad M; Verner E; Loury D; Chang B; Li S; Pan Z; Thamm DH; Miller RA; Buggy JJ
    Proc Natl Acad Sci U S A; 2010 Jul; 107(29):13075-80. PubMed ID: 20615965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bruton's tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment.
    Good L; Benner B; Carson WE
    Cancer Immunol Immunother; 2021 Sep; 70(9):2439-2451. PubMed ID: 33818636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Research Progress of BTK Inhibitors in the Treatment of Autoimmune Diseases.
    Lin P; Zhang D; Lin J
    Curr Top Med Chem; 2023; 23(28):2609-2620. PubMed ID: 37861005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel dual Bruton's tyrosine kinase (BTK) and Janus kinase 3 (JAK3) inhibitors as a promising strategy for rheumatoid arthritis.
    Liang T; Cen L; Wang J; Cheng M; Guo W; Wang W; Yu C; Zhang H; Wang Y; Hao Z; Jin J; Wu Y; Jiang T; Zhu Q; Xu Y
    Bioorg Med Chem; 2023 Dec; 96():117354. PubMed ID: 37944414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bruton's Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease.
    Neys SFH; Rip J; Hendriks RW; Corneth OBJ
    Drugs; 2021 Sep; 81(14):1605-1626. PubMed ID: 34609725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitors of Bruton's tyrosine kinase as emerging therapeutic strategy in autoimmune diseases.
    De Bondt M; Renders J; Struyf S; Hellings N
    Autoimmun Rev; 2024 May; 23(5):103532. PubMed ID: 38521213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoparticle-delivered siRNA targeting Bruton's tyrosine kinase for rheumatoid arthritis therapy.
    Zhao G; Liu A; Zhang Y; Zuo ZQ; Cao ZT; Zhang HB; Xu CF; Wang J
    Biomater Sci; 2019 Nov; 7(11):4698-4707. PubMed ID: 31495833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bruton's Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials.
    Rozkiewicz D; Hermanowicz JM; Kwiatkowska I; Krupa A; Pawlak D
    Molecules; 2023 Mar; 28(5):. PubMed ID: 36903645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bruton's Tyrosine Kinase mediates platelet receptor-induced generation of microparticles: a potential mechanism for amplification of inflammatory responses in rheumatoid arthritis synovial joints.
    Hsu J; Gu Y; Tan SL; Narula S; DeMartino JA; Liao C
    Immunol Lett; 2013 Feb; 150(1-2):97-104. PubMed ID: 23266841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models.
    Haselmayer P; Camps M; Liu-Bujalski L; Nguyen N; Morandi F; Head J; O'Mahony A; Zimmerli SC; Bruns L; Bender AT; Schroeder P; Grenningloh R
    J Immunol; 2019 May; 202(10):2888-2906. PubMed ID: 30988116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amplification of IL-21 signalling pathway through Bruton's tyrosine kinase in human B cell activation.
    Wang SP; Iwata S; Nakayamada S; Niiro H; Jabbarzadeh-Tabrizi S; Kondo M; Kubo S; Yoshikawa M; Tanaka Y
    Rheumatology (Oxford); 2015 Aug; 54(8):1488-97. PubMed ID: 25724205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bruton's Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis.
    Arneson LC; Carroll KJ; Ruderman EM
    Immunotargets Ther; 2021; 10():333-342. PubMed ID: 34485183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.